The current lack of objective biomarkers presents a real challenge for researchers developing treatments for psychiatric and neurological diseases. But now, a partnership that combines Calyx’s clinical trial imaging expertise and Ceretype’s novel functional MRI (fMRI) platform enables trial sponsors to overcome this challenge and see the physical action of a drug on patients with psychiatric and other neurological disorders.
作为市场上通过正式认证的"生物标志物引擎"，Ceretype 平台利用业内领先的 fMRI 和人工智能 (AI) 将神经回路与患者的行为和治疗结果联系起来，提供研究人员所需的客观生物终点，并可在中枢神经系统 (CNS) 药物开发期间，帮助研究人员更精确地实现对治疗效果的测量。
During this webinar, Calyx and Ceretype’s scientists will:
- Review traditional fMRI challenges and how Ceretype’s groundbreaking platform addresses them.
- Discuss the implications that this novel, scalable solution could have on clinical development, and what Ceretype is doing to ensure real-world access to its technology.
- Explore case studies of how Ceretype’s platform is changing the way that drug developers think about fMRI, and how it can enhance their development programs.
时间
2023 年 11 月 2 日
10AM-11AM ET
发言人
Rohit Sood
Vice President, Scientific & Medical Services
Rohit Sood MD., PhD. is the Vice President of Scientific and Medical Services at Calyx. In his present role as the Emerging Therapeutics Lead, which covers Cardio-Thoracic, CNS, GI, Rare diseases and Advanced Technologies, Dr. Sood has contributed as a consultant/scientific lead on sponsored 160+ imaging clinical trials spanning the entire spectrum, from early to late phase, across multiple therapeutic areas. He was responsible for supporting 20+ drug approval clinical studies that involved imaging as a key trial endpoint. Over the past decade, he has been instrumental in developing partnerships with academic and non-academic labs to leverage Machine and Deep Learning methodologies for application in pharmaceutical drug studies that involve imaging based endpoints. More specifically, using ML/DL methods to analyze images and develop quantitative biomarkers for use as endpoints in clinical trials. The usefulness of some of these biomarkers was evaluated in clinical trials and results were published in peer reviewed scientific journals.
